Japan’s Matsushita Develops New DNA Technology For Drug Response
This article was originally published in PharmAsia News
Matsushita Electric Industrial of Japan reports it has developed a technology that identifies DNA sequence variations electronically for predicting responses to drugs. The system dissolves artificial DNA in a solution instead of attaching it to an electrode, enabling technicians to predict an individual's response to drugs and risk of developing a particular disease. Matsushita refers to the technology as "single nucleotide polymorphisms." (Click here for more
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.